Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Inhaled TPI 1100 in Healthy Volunteers
NCT00914433 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL
Last updated 2012-12-03
Summary
This study will look at the safety and tolerability of TPI 1100 in healthy volunteers and look at pharmacodynamic (PD) effect on mRNA expression of PDE 4B/D \& 7A in blood and in sputum.
Conditions
Interventions
- DRUG
-
TPI 1100
1 dose only increasing dose
Sponsors & Collaborators
-
Syntara
lead INDUSTRY
Principal Investigators
-
Pageau · Topigen Pharmaceuticals Inc.
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- TRIPLE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 55 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2009-04-30
- Primary Completion
- 2009-12-31
- Completion
- 2010-04-30
More Related Trials
-
A Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of SM04646 Inhalation Solution in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
NCT03591926 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Study of Safety & Blood Levels of IDL-2965 in Healthy Subjects and Patients With a Special Type of Pulmonary Fibrosis
NCT03949530 ·Status: TERMINATED ·Phase: PHASE1
-
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Inhaled XQ-001 in Healthy Subjects
NCT06918366 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
A Safety, Tolerability, and Pharmacokinetic Study of NIP292 in Healthy Normal Subjects
NCT04720443 ·Status: COMPLETED ·Phase: PHASE1
-
Single Doses of GSK3008348 in Idiopathic Pulmonary Fibrosis (IPF) Participants Using Positron Emission Tomography (PET) Imaging
NCT03069989 ·Status: TERMINATED ·Phase: PHASE1
-
Study in Healthy Adults to Quantify Lung Deposition and Distribution of Radio-labelled S-770108 Inhalation Powder Formulation Delivered by a Novel Inhaler Device
NCT04631354 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase 2 Study to Evaluate the Safety and Tolerability of PBI-4050 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
NCT02538536 ·Status: COMPLETED ·Phase: PHASE2
-
Placebo-controlled, Single and Multiple Dose Study in Healthy Volunteers and Refractory Chronic Cough Patients to Assess the Safety, Tolerability, and Pharmacokinetics of Two Formulations of NTX-1175
NCT05628740 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Test How Taking BI 1015550 for 12 Weeks Affects Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
NCT04419506 ·Status: COMPLETED ·Phase: PHASE2
-
Safety, Tolerability, and Pharmacokinetic Study of TRK-250 for Patients With Idiopathic Pulmonary Fibrosis
NCT03727802 ·Status: COMPLETED ·Phase: PHASE1
-
Phase I Study of CPD704 Inhalation Suspension in Healthy Subjects
NCT07301203 ·Status: RECRUITING ·Phase: PHASE1
-
Study of Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of VAY736 in Patients With Idiopathic Pulmonary Fibrosis
NCT03287414 ·Status: TERMINATED ·Phase: PHASE2
-
A Study in Patients With Non-cystic Fibrosis Bronchiectasis to Test How Well Different Doses of BI 1323495 Are Tolerated and How BI 1323495 Affects Biomarkers of Inflammation
NCT04656275 ·Status: TERMINATED ·Phase: PHASE1
-
Study on Intravenous Injection of SHR-1906 in the Treatment of Idiopathic Pulmonary Fibrosis
NCT05722964 ·Status: COMPLETED ·Phase: PHASE2
-
PT001 MDI Versus Spiriva® in Patients With Moderate to Severe COPD
NCT01566773 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of RV6153
NCT02517359 ·Status: TERMINATED ·Phase: PHASE1
-
A Trial of SHR - 1906 in Healthy Subjects
NCT04986540 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Investigate the Safety Tolerability Pharmacokinetics, and Pharmacodynamics of Inhaled and Intravenous GSK2862277 in Healthy Volunteers
NCT01818024 ·Status: COMPLETED ·Phase: PHASE1
-
Effect of Tiotropium on Exercise Tolerance in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT02172300 ·Status: COMPLETED ·Phase: PHASE3
-
A First in Human Study of the Safety, Tolerability, and the Physiologically Based Pharmacokinetics of XFB19 in Healthy Adult Volunteers.
NCT05361733 ·Status: RECRUITING ·Phase: PHASE1
-
Phase 1, Safety and Bronchopulmonary PK Study in Healthy Volunteers
NCT03691584 ·Status: COMPLETED ·Phase: PHASE1
-
INB03 for the Treatment of Pulmonary Complications From COVID-19
NCT04370236 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
Safety and Pharmacokinetic (PK) Study to Assess Bronchopulmonary Disposition of IV Eravacycline (TP-434) in Healthy Men and Women
NCT01989949 ·Status: COMPLETED ·Phase: PHASE1
-
To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF)
NCT01529853 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Clinical Trial on the Treatment of Idiopathic Pulmonary Fibrosis
NCT06102083 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2